Cross-border emergence of Escherichia coli producing the carbapenemase NDM-5 in Switzerland and Germany
Chakraborty, TrinadInstitute of Medical Microbiology, and German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, Justus Liebig University Giessen, Giessen, Germany - Institute of Hygiene and Environmental Medicine, Justus Liebig University Giessen, Giessen, Germany
Sadek, MustafaMedical and Molecular Microbiology, Section of Medicine, Faculty of Science and Medicine, University of Fribourg, Switzerland
Yao, YanchengInstitute of Medical Microbiology, and German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, Justus Liebig University Giessen, Giessen, Germany - Institute of Hygiene and Environmental Medicine, Justus Liebig University Giessen, Giessen, Germany
Imirzalioglu, CanInstitute of Medical Microbiology, and German Center for Infection Research (DZIF), Partner Site Giessen-Marburg-Langen, Justus Liebig University Giessen, Giessen, Germany - Institute of Hygiene and Environmental Medicine, Justus Liebig University Giessen, Giessen, Germany
Stephan, RogerInstitute for Food Safety and Hygiene, Vetsuisse Faculty University of Zurich, Zurich, Switzerland
Poirel, LaurentMedical and Molecular Microbiology, Section of Medicine, Faculty of Science and Medicine, University of Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Switzerland - Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Switzerland
Nordmann, PatriceMedical and Molecular Microbiology, Section of Medicine, Faculty of Science and Medicine, University of Fribourg, Switzerland - INSERM European Unit (IAME, France), University of Fribourg, Switzerland - Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Switzerland - Institute for Microbiology, University of Lausanne and University Hospital Centre, Lausanne, Switzerland
English
A series of clinical NDM-5-producing E. coli isolates obtained from two surveillance networks of carbapenem-producing Enterobacterales from 2018-2019, namely Switzerland (NARA) and Germany (SurvCARE), were analyzed. The 33 NDM-5- producing E. coli isolates were highly resistant to β-lactams including the novel ß- lactam/ß-lactamase inhibitor combinations (ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam), and remained susceptible to fosfomycin, colistin, and tigecycline. Those isolates were assigned to different sequence types (STs) and indicated a predominance of isolates exhibiting the sequence type (ST) ST167 in Switzerland and in Germany (n=10, phylogenetic group C), followed by ST405 (n=4, phylogenetic group E), ST1284 (n=4, phylogenetic group C) and ST361 (n=4, phylogenetic group C). The blaNDM-5 gene was predominantly present on an IncF-type plasmid (n=29), and to a lesser extent on the narrow-host range IncX3 plasmid (n=4). Sequence analyses of eight NDM-5 plasmids indicated that NDM-5-encoding F-type plasmids varied in size between 86 to 132 kb. The two IncX3 plasmids pCH8NDM5 and pD12NDM5 were 46 and 45 kb in size, respectively. The highly conserved blaNDM-5 genetic surrounding structures [ΔISAba125-blaNDM- 5-bleMBL-trpT-dsbD-IS26] of both the F-type and IncX3 plasmids suggested a common genetic origin. The emergence of the NDM-5 carbapenemase was evidenced in particular for the E. coli ST167 clone, which is a successful epidemic clone, known to be associated to both multi-resistance and virulence traits and is therefore of high public health concern. The occurrence of clonally related NDM-5- producing E. coli isolates in Switzerland and Germany further indicates the international spread of this multidrug-resistant superbug at least throughout Europe.